Characterization of purinergic receptor 2 signaling in podocytes from diabetic kidneys

Oleg Palygin, Christine A. Klemens, Elena Isaeva, ..., Oksana Nikolaienko, Daria V. Ilatovskaya, Alexander Staruschenko

staruschenko@mcm.edu

Highlights
Diabetic podocytes have sustained intracellular Ca²⁺ signaling in response to ATP
Podocyte purinergic receptor signaling is predominantly ionotropic in diabetes
Both type 1 and 2 diabetic podocytes have similar purinergic receptor remodeling

Remodeling of purinergic receptor 2 signaling in podocytes during the progression of diabetic kidney disease

CONCLUSIONS
The pathological remodeling in purinergic signaling from metabotropic to ionotropic P2X₄ and P2X₇ receptors may contribute to podocyte loss and kidney injury in diabetes as it results in increased basal and ATP-stimulated [Ca²⁺], likely exacerbating podocyte damage and apoptosis, and further aggravating DKD progression.
Characterization of purinergic receptor 2 signaling in podocytes from diabetic kidneys

Oleg Palygin, Christine A. Klemens, Elena Isaeva, Vladislav Levchenko, Denisha R. Spires, Lashodya V. Dissanayake, Oksana Nikolaienko, Daria V. Ilatovskaya, and Alexander Staruschenko

SUMMARY
Growing evidence suggests that renal purinergic signaling undergoes significant remodeling during pathophysiological conditions such as diabetes. This study examined the renal P2 receptor profile and ATP-mediated calcium response from podocytes in glomeruli from kidneys with type 1 or type 2 diabetic kidney disease (DKD), using type 2 diabetic nephropathy (T2DN) rats and streptozotocin-injected Dahl salt-sensitive (type 1 diabetes) rats. A dramatic increase in the ATP-mediated intracellular calcium flux in podocytes was observed in both models. Pharmacological inhibition established that P2X4 and P2X7 are the major receptors contributing to the augmented ATP-mediated intracellular calcium signaling in diabetic podocytes. The transition in purinergic receptor composition from metabotropic to ionotropic may disrupt intracellular calcium homeostasis in podocytes resulting in their dysfunction and potentially further aggravating DKD progression.

INTRODUCTION
Diabetes is a severe chronic disorder characterized by impaired glucose metabolism mechanisms that leads to increased blood sugar levels, thereby damaging many vital corporeal systems, including cardiovascular, urinary, nervous systems, and vision. A major risk factor affecting patients with diabetes is an increased probability of developing diabetic kidney disease (DKD). Diabetes and its complications, including diabetic nephropathy (DN), are a significant cause of increased morbidity and mortality among people with diabetes, and a main risk factor for end-stage kidney disease. DN is a specific diagnosis referring to distinct pathologic structural and functional renal changes caused by diabetes and is distinguished by proteinuria, glomerular basement membrane thickening, mesangial expansion, GFR changes, and arterial hyalinosis, with progressive loss of renal function (Umanath and Lewis, 2018). Identification of mechanisms leading to DKD associated renal damage may accelerate the development of new therapies aiming to slow or prevent disease progression.

Clinical and experimental studies suggest that purinergic signaling is an important contributor to various physiological and pathophysiological processes in the kidney, including diabetes (Vallon et al., 2020). For example, ionotropic P2X7 receptors are implicated in cyst formation in polycystic kidney disease and also renal interstitial inflammation associated with different kidney pathologies (Arkhipov et al., 2019; Chang et al., 2011; Goncalves et al., 2006; Taylor et al., 2009a). Renal proximal tubular P2X4 activation promotes tubular inflammation and exacerbates ischemic acute kidney injury (Han et al., 2020), and deficient metabotropic P2Y2 signaling has been shown to aggravate the progression of chronic kidney disease in mice (Potthoff et al., 2013). P2Y2 was also reported as critical receptor in the control of ENaC-mediated sodium transport in the collecting duct (Mironova et al., 2019; Stockand et al., 2010). Furthermore, purinergic signaling is of additional interest due to the currently available pharmacopeia of P2 agonists and antagonists that may be useful therapeutic agents for various diseases, including hypertension and diabetes.

Microvascular dysfunction and alterations of glomerular filtration barrier (GFB) are early features of DKD progression. The GFB consists of endothelial cells, basement membrane, and podocytes (epithelial cells). Podocytes are highly specialized cells that maintain the integrity of the GFB, but progressive damage over time resulting from disease conditions causes podocyte loss and GFB dysfunction as they are non-proliferative. Diabetes can cause foot process effacement, podocyte cell death, and loss of GFB integrity, all of which are prognostic indicators of DKD (Mitrofanova et al., 2019; Vallon and Komers, 2011). We recently
The aim of this study was to characterize podocyte purinergic signaling in type 1 diabetes (T1D) and type 2 diabetes (T2D) with DN. To do this, we used the type 2 diabetic nephropathy (T2DN) rat model whose renal phenotype has recently been thoroughly characterized (Nobrega et al., 2004; Palygin et al., 2019). T2DN rats were compared to non-diabetic control rats (Wistar) and diabetic rats that do not develop severe DN (Goto-Kakizaki [GK] (Goto et al., 1976)). For T1D, we utilized the established experimental model of streptozotocin (STZ)-injected Dahl salt-sensitive (SS) rats (Korner et al., 1997; Miller et al., 2018; Slaughter et al., 2013; Spires et al., 2018). We assessed the ATP-mediated [Ca2+]i flux in podocytes during the progression of DKD. A distinct advantage of our approach is that podocyte signaling characterization is performed in podocytes of intact freshly isolated glomeruli; thus, the podocytes are exposed to whole organ and systemic changes until the end point experiments providing a more physiologically accurate environment than experiments conducted with cultured cells. The specific role of different subtypes of P2 receptors and the relative remodeling in [Ca2+]i homeostasis were analyzed ex vivo using fluorescent confocal imaging of freshly isolated glomeruli and commercially available pharmacological tools. Our results demonstrate the purinergic receptor profile of podocytes in T1D and T2D have a significant increase in ionotropic calcium flux, mainly mediated by low affinity P2X4 and P2X7 receptors, whereas the contribution of metabotropic P2Y1 signaling is decreased compared to healthy, non-diabetic podocytes. Furthermore, changes to basal Ca2+ concentrations and ATP response is present in early stage T2D diabetic kidneys before development of substantial renal damage. We verify that P2X4 and P2X7 activity is an additional pathological change which results in prolonged [Ca2+]i levels and signaling, likely creating a feedforward mechanism that exacerbates podocyte apoptosis in the late-stages of diabetes. These results provide mechanistic insight into purinergic control of [Ca2+]i in podocytes.

RESULTS

Experimental models of T1D and T2D

In order to characterize podocyte purinergic signaling in diabetes, we used well established models of T1D and T2D, namely the STZ-injected Dahl SS rat and the T2DN rat, respectively (Korner et al., 1997; Nobrega et al., 2004; Slaughter et al., 2013; Spires et al., 2018). Controls for T1D conditions were vehicle-injected Dahl SS rats, while for T2DN, controls included both a non-diabetic (Wistar) rat strain and a diabetic rat strain that does not develop severe DN (GK) rats (Palygin et al., 2019). The STZ-injected Dahl SS rat model closely mimics functional and morphological characteristics of human T1D DN, as it exhibits severe glomerulosclerosis, interstitial fibrosis, mesangial matrix expansion and proteinuria, and has previously been well characterized by us and others (Korner et al., 1997; Miller et al., 2018; Slaughter et al., 2013). Similarly, T2DN rats exhibit increased medullary protein casts, kidney fibrosis, and glomerular injury compared to GK or Wistar rats (Nobrega et al., 2004; Palygin et al., 2019). Diabetes and renal damage were verified by blood glucose levels and albuminuria (Figure 1). To assess changes in renal purinergic P2 signaling during early and late-stage T2D, male Wistar, GK, and T2DN rats at 12 and >48 weeks old were used. At the age of 12 weeks, both diabetic strains, T2DN and GK, display hyperglycemia but no significant albuminuria or change in total body weight (Figure 1B). At 48 weeks, T2DN rats show significant albuminuria, indicating glomerular disease. In our late-stage T1D model, blood glucose and albuminuria are substantially increased relative to controls, and total body weight is significantly decreased (Figure 1A).

Basal intracellular calcium levels and transient response to extracellular ATP is elevated in podocytes from T2D kidneys

To evaluate changes in intracellular calcium ([Ca2+]i) homeostasis and response to ATP in podocytes during T2D, we conducted live-cell Ca2+ fluorescence imaging in freshly isolated glomeruli from 12-week-old rats. Podocytes of T2DN rats have significantly greater basal [Ca2+]i levels relative to non-diabetic (Wistar) or a diabetic rat without DN (GK), indicating cellular stress (Figure 2A). Acute application of ATP produced rapid transient activation of [Ca2+]i in podocytes, as shown Figures 2B and 2C (see also Video S1). Activation of P2 receptors
in T2DN rat podocytes is characterized by a prolonged \([\text{Ca}^{2+}]_i\) transient (Figure 2C), and significant increase in total \([\text{Ca}^{2+}]_i\) (calculated from area under the curve (AUC) from individual cell traces) The data are summarized in Figure 2D. These experiments demonstrate that podocytes have augmented basal and purinergic \([\text{Ca}^{2+}]_i\) signaling even before onset of clinically relevant renal damage indicators such as albuminuria.

Expression of P2 receptors in the renal cortex at different stages of DKD

In order to determine possible changes in purinergic signaling during the development of diabetic kidney injury in T2DN rats, we profiled P2 receptors expression in the renal cortex of 12- and 48-week-old animals. Figure 3 illustrates the expression of metabotropic P2Y1, P2Y2, and P2Y12 (Figure 3A) and ionotropic P2X4 and P2X7 (Figure 3B) receptors in the cortical tissue of the 12-week-old Wistar, T2DN, and GK rats. The increase in the expression of P2X7 protein was confirmed using a highly specific antibody directed against an extracellular epitope of P2X7 (Figure 3B, bottom panel). Diabetic conditions at 12 weeks moderately affected the cortical abundance of metabotropic purinergic receptors with a significant decline in P2Y1 expression in GK and trending decline in T2DN rats. In contrast, the expression of ionotropic P2X4 and P2X7 receptors was significantly elevated in both diabetic strains at 12 weeks of age (Figure 3B), similar what has been observed in patients with T2D (Chen et al., 2013; Solini et al., 2013). Interestingly, the expression of P2X4 was more pronounced in aged T2DN than in GK rats, as the GK P2X4 renal cortex expression was not significantly increased compared to Wistar in the aged (>48 weeks old) rats (Figure 4B). In 48-week-old rats, P2Y1 was significantly decreased in both GK and T2DN rats (Figure 4). In addition, mRNA levels were assessed in the cortical renal tissue of 12-week-old animals using qPCR analysis. Our data show a dramatic change in P2x4 and P2x7 gene expression without alteration of P2ry1 and P2ry2 expression in the renal cortex of GK and T2DN rats compared to non-diabetic Wistar rats (Figure S1).

P2 receptor signaling in podocytes of DN rats

In our previous study, we demonstrated that P2Y1 is the major purinoceptor contributing to ATP-induced \([\text{Ca}^{2+}]_i\) response in rat podocytes under normal physiological conditions (Ilatovskaya et al., 2013). However, Western blot and qPCR data from kidney cortex of control and T2DN rats indicate that there is a substantial change in the expression profile of various P2 receptors in the renal cortex of diabetic rats with a shift of their balance from metabotropic to ionotropic signaling. To test the functional presence of P2X4 and
P2X7 receptors in podocytes during advanced DN, we investigated the effect of pharmacological inhibition of ATP-mediated \([Ca^{2+}]_i\) flux in adult T2DN rats (>48-weeks-old). Application of ATP produces a robust transient response in podocytes from freshly isolated T2DN glomeruli (Figure 5, representative transients without inhibitors are in gray). The ATP-induced \([Ca^{2+}]_i\) response was significantly blunted in the presence of specific P2X4 (10 \(\mu\text{M} 5\text{-BDBD}) or P2X7 (10 \(\mu\text{M} A438079) antagonists and was dramatically reduced when both P2X4 and P2X7 antagonists were combined, indicating a major contribution of these receptors to ATP-mediated \([Ca^{2+}]_i\) signaling in podocytes of T2DN rats (Figure 5).

Characterization of renal P2 receptors in T1D

Figure 6A (see also Video S2) shows representative images of \([Ca^{2+}]_i\) fluorescence changes in podocytes of freshly isolated glomeruli from control and type 2 diabetic rats. Application of ATP produces a robust transient response in podocytes from freshly isolated T2DN glomeruli (Figure 5, representative transients without inhibitors are in gray). The ATP-induced \([Ca^{2+}]_i\) response was significantly blunted in the presence of specific P2X4 (10 \(\mu\text{M} 5\text{-BDBD}) or P2X7 (10 \(\mu\text{M} A438079) antagonists and was dramatically reduced when both P2X4 and P2X7 antagonists were combined, indicating a major contribution of these receptors to ATP-mediated \([Ca^{2+}]_i\) signaling in podocytes of T2DN rats (Figure 5).
To delineate the contribution of various P2 receptors in ATP-induced $[\text{Ca}^{2+}]_i$ signaling in T1D podocytes, specific blockers of metabotropic P2Y1 (MRS2500) and ionotropic P2X4 and P2X7 receptors (5-BDBD; A438079) were used. Summary transients recorded from T1D podocytes pretreated with inhibitor (black) compared to untreated T1D podocytes (gray) and control podocytes (light gray) are shown in Figure 7A. Using AUC measurements to determine the magnitude of $[\text{Ca}^{2+}]_i$ over the time period, and calculating them as a percentage of the AUC measurement from untreated T1D podocytes allowed us to determine the percent contribution of the different P2 receptors. This percentage of inhibition is shown in Figure 7B and summarizes the effect of application of P2Y1, P2X4 and P2X7 either alone or in combination on $[\text{Ca}^{2+}]_i$ response. Treatment with the P2Y1 antagonist had a moderate effect on the $[\text{Ca}^{2+}]_i$ transient (~15% reduction). Inhibition of P2X4 or P2X7 reduced the prolonged $[\text{Ca}^{2+}]_i$ signal (~40% and ~26%, correspondingly). Antagonism of both P2X4 and P2X7 resulted in a response curve more closely resembling the transient signal of healthy podocytes, and these ionotropic receptors contributed to ~43% block of the calcium signal. Finally, pretreatment of T1D glomeruli with all three inhibitors substantially decreased podocyte $[\text{Ca}^{2+}]_i$ response to 40 μM ATP, suggesting P2Y1, P2X4, and P2X7 account for ~80% of the total $[\text{Ca}^{2+}]_i$, transient. These data indicate that, in contrast to data obtained previously from podocytes of healthy Sprague-Dawley rats (Ilatovskaya et al., 2013), both T1D and T2D conditions result in a dramatic shift to ionotropic P2 receptor ATP-induced $\text{Ca}^{2+}$ flux. We also verified that pretreatment with P2X4 and P2X7 inhibitors does not affect the ATP-evoked $[\text{Ca}^{2+}]_i$, transient in healthy, age-matched control Dahl SS rats (Figure S2), demonstrating that similar to our previous results in Sprague-Dawley rats, functionally active P2X4 or P2X7 are not a major contributor to healthy Dahl SS podocyte ATP-mediated $[\text{Ca}^{2+}]_i$, response. The presence of P2X4 in diabetic podocytes was also verified by immunofluorescent labeling of P2X4 with the podocyte-marker, nephrin, in a freshly isolated T1D glomerulus (Figure S3).

DISCUSSION
Under normal physiological conditions, extracellular ATP levels are low due to the activity of numerous ATP-metabolizing endogenous enzymes (Schwiebert and Zsembery, 2003); however pathological changes result in increased extracellular ATP concentrations and purinergic signaling. We previously demonstrated that basal extracellular concentrations of ATP in the renal cortex can go as high as 400 nM (Palygin et al., 2013), that extracellular ATP increases dramatically in response to increased renal perfusion pressure...
and that in pathological conditions like PKD, ATP levels can exceed 1 μM (Palygin et al., 2018). In agreement with these findings, human studies have found significant increases in the plasma levels of purine metabolites of patients with DN compared to patients with T2D without nephropathy (Xia et al., 2009). Pathological changes resulting from diabetes, especially in the late stages with multi-organ systemic damage, may potentially increase extracellular ATP concentrations in the kidney, therefore greater insight into the purinergic signaling profile of diabetic podocytes is essential to further therapeutic treatment options (Burnstock and Novak, 2013).

Functionally, all three diabetic rats (GK, T2DN, and STZ-induced T1D) demonstrated augmented ATP-mediated [Ca^{2+}]_{i} responses compared to age-matched non-diabetic Wistar and Dahl SS rats. This alteration in Ca^{2+} homeostasis could lead to a number of detrimental cellular processes, including cytoskeletal modifications that alter cell shape and foot process dynamics; activation of Ca^{2+}-dependent catabolic enzymes (proteases, phospholipases, endonucleases) causing membrane damage, and signaling pathways leading to cell death. The deleterious nature of excessive intracellular Ca^{2+} and its association with apoptosis has been well established for several decades (Fleckenstein et al., 1983; Nicotera and Orrenius, 1998; Rizzuto et al., 2003). Calcium overload can occur through both intra- and extracellular routes, and dysregulation of these homeostatic mechanisms has been shown to be associated with cell death in a number of different cell types (Fleckenstein et al., 1983; Nicotera and Orrenius, 1998; Rizzuto et al., 2003). While we have not directly confirmed that the increased basal Ca^{2+} and

Figure 4. Expression of P2 receptors in renal cortex of old rats
Western blot images and corresponding summary graphs showing densitometric analysis of P2Y1 (A), P2X4, and P2X7 (B) protein expression levels in renal cortex of the aged (>48-weeks-old) Wistar, GK and T2DN rats. All Western blot values were normalized to loading control (β-actin or Gapdh). Significance (p < 0.05) is indicated by *, Tukey’s multiple-comparison adjustment was applied. In the box plot graphs, the box represents ± SE, and a line inside the box marks the median. The whiskers are ± SD.
augmented Ca\(^{2+}\) transients lead to apoptosis in our diabetic podocytes, future studies will more thoroughly verify this transition from this excess [Ca\(^{2+}\)] to apoptosis or other forms of cell death by assessing caspase cleavage and DNA breakage in podocytes from isolated glomeruli following acute ATP application or inactive ATP analog.

Under normal physiological conditions in podocytes, metabotropic G protein-coupled receptor signaling (including P2Y\(_1\), P2Y\(_2\) and P2Y\(_6\)) predominates and works by activating TRPC6 signaling and regulating ROS production in the cell (Burford et al., 2014; Fischer et al., 2001; Roshanravan and Dryer, 2014). Our studies demonstrate diabetic podocytes have a distinct purinergic signaling profile compared to non-diabetic podocytes with augmented ATP-mediated [Ca\(^{2+}\)] flux; however, what specific trigger or combination of stimuli in diabetes causes this transition remains to be determined. Potential causes may include increased blood glucose concentrations, immune cell infiltration, altered blood pressure, glomerular perfusion pressure, altered extracellular ATP levels or a range of factors, and additional experiments, such as those that would allow for continuous glucose control in rats by preventing or inducing hyperglycemia will more methodically delineate these potential causes.

Figure 5. Ionotropic P2X\(_4\) and P2X\(_7\) receptors play a predominant role in ATP-induced increase in [Ca\(^{2+}\)], in podocytes of T2DN rats

Summary of changes in the ATP evoked [Ca\(^{2+}\)] transient in the absence or presence of P2X\(_4\) and P2X\(_7\) antagonists separately or together: (A) 10 \(\mu\)M A438079 - P2X\(_7\) antagonist; (B) 10 \(\mu\)M 5-BDBD - P2X\(_4\) inhibitor, and (C) both antagonists in T2DN rats. [Ca\(^{2+}\)] transients were induced by application of 100 \(\mu\)M ATP.

Summary graphs to the right of the averaged response show the relative amplitude of ATP-induced [Ca\(^{2+}\)] flux. * indicates statistical significance (p < 0.05) as determined by student t-test. In the box plot graphs, the box represents \(\pm\) SE, and a line inside the box marks the median. The whiskers are \(\pm\) SD.
Our experiments in both T1D and T2D podocytes with specific inhibitors provide compelling evidence that P2X4 and P2X7 receptors play a major role in ATP-induced [Ca^{2+}] levels in diabetic podocytes. Previous research has established that P2X7 receptor expression increases are linked to PKD, glomerulonephritis, human lupus nephritis, and hypertension-associated renal injury (Arkhipov et al., 2019; Hillman et al., 2005; Pereira et al., 2020; Vallon et al., 2020). In addition, the upregulation of glomerular P2X7 receptor mRNA and protein expression has been reported in STZ-induced diabetic and ren-2 transgenic hypertensive rat models, and was associated with inflammatory cytokine release and cell death (Vonend et al., 2004a). Studies have also shown that pharmacological inhibition or deletion of P2X7 receptor offers varying degrees of protection in these pathologies (Arkhipov et al., 2019; Ji et al., 2012; Menzies et al., 2015, 2017a, 2017b; Pereira et al., 2020; Taylor et al., 2009b). Here we show that podocytes in late-stage diabetes mellitus have direct ionotropic P2 calcium entry through the pore-forming P2X_{4,7} channels in addition to metabotropic signaling through P2Y1. While still speculative, this ATP-mediated Ca^{2+} flux in podocytes may contribute to pathological changes in diabetes by instigating cell damage and podocyte cell death. Our data also demonstrate significant differences in renal cortex expression of several P2 receptors in diabetes; however, it is important to note that these changes occur in whole kidney cortex lysates, and direct comparisons to the functional podocyte signaling data cannot be made.

Although we did not interrogate functional P2 activity for all glomerular cells in diabetes in the present work, a few recent single-cell transcriptomic studies have begun to investigate transcriptomic profiles in individual cells (Chung et al., 2020; Fu et al., 2019; Wilson et al., 2019). Of particular interest is the study from Wilson et al. (2019) profiling single-cell transcriptomics from early human DN, and the easily

Figure 6. Intracellular Ca^{2+} ([Ca^{2+}]_i) response to ATP in T1D
(A) Representative images of control or T1D glomeruli at baseline (1), immediately following application of 40 μM ATP (2), or 5 min post application (3). Glomeruli were isolated from STZ- (T1D) or vehicle-injected control Dahl SS rats loaded with Fluo4 and FuraRed dyes for ratiometric calcium imaging. Note the prolonged signal in the T1D podocytes compared to controls (arrows). Only images from the Fluo4 channel are shown.
(B) Averaged curves of [Ca^{2+}]_i changes from control (light gray) or T1D (gray) podocytes. Arrows indicate time points (1, 2, and 3) of images shown in (A).
(C) Summarized data of the peak amplitude and (D) [Ca^{2+}]_i transient (quantified as the total area under the curve) in response to ATP in STZ-SS and control rats. Individual points are cells. * indicates statistical significance, p < 0.05, as determined by unpaired student t-test. In the box plot graphs, the box represents ± SE, and a line inside the box marks the median. The whiskers are ± SD.
searchable online data set provided by the Humphrey Lab available at http://humphreyslab.com/SingleCell/(Wilson et al., 2019). Using the search function of the human diabetic kidney set, podocyte-specific changes in P2 receptor expression can be easily queried by gene name. Similar to our functional results, in this dataset P2RX7 expression increases while P2RY1 expression decreases. There appears to be no change in P2RY2 or P2RX4 expression. The advantage of our study is that it shows the profound functional effects resulting from this unique purinergic profile, namely different calcium signaling responses to ATP and potential dysregulation of basal calcium homeostasis. This provides greater mechanistic support to the idea that the increased contribution of P2X4 and P2X7 receptor activity to ATP-dependent Ca2+ dynamics occurring in diabetes may exacerbate DN damage in podocytes. Also of note is the potential for P2X4 and P2X7 to interact and influence the electrophysiological properties of one another (Craigie et al., 2013; Guo et al., 2007; Nicke, 2008; Perez-Flores et al., 2015; Schneider et al., 2017). P2X4 and P2X7 are able to co-immunoprecipitate with one another (Guo et al., 2007), and some studies have shown functional current changes when P2X4 and P2X7 are co-expressed suggesting they form heteromers (Guo et al., 2007), although others have not (Nicke, 2008). While only conjecture, altered current kinetics resulting from P2X4/P2X7 heteromers may explain the prolonged calcium signal observed in the late stage T1D podocytes which fails to return to baseline levels. Additionally, while P2X4 is present in both normal and diabetic podocytes, perhaps it requires the upregulation of P2X7 that occurs in late-stage diabetes in order to influence ATP-mediated [Ca2+]i. Further studies are needed to examine this potential interaction in diabetic podocytes.

In summary, these data demonstrate the dramatic increase in ionotropic P2 receptor podocyte signaling, with P2X4 and P2X7 contributing to ATP-mediated [Ca2+]i flux in DKD in both T1D and T2D. Future studies treating T1D or T2D rats during the development of end stage diabetes with P2X4 and P2X7 antagonists will determine whether pharmacological intervention may be able to attenuate pathological Ca2+ signaling and prevent exacerbation of cellular damage and apoptosis.
Limitations of the study

While we feel the data from these experiments provides strong support for the change in ATP-mediated signaling from metabotropic to ionotropic signaling in diabetic podocytes, this study still has several limitations. First, this study utilized males and did not examine potential sexual dimorphisms in purinergic podocyte signaling, which will be interesting to examine in future studies. Additionally, this study did not take into consideration potential differences from diet. Dahl SS rats (vehicle- and STZ-injected) were maintained on standard 0.4% NaCl AIN-76 diet (#D113755), whereas the Wistar/GK/T2DN rats were maintained on a Purina LabDiet (Cat#5001). Transcriptional and translational changes in purinergic receptor expression profiles were determined from kidney cortex rather than glomerular fractions due to the limited availability of ex vivo tissue for experiments; therefore the reported expression changes are global rather than podocyte-specific, so comparisons of the Western blot results to direct functional data of podocyte signaling cannot be made without further co-localization studies. Experimentally, one technical flaw is the inability to pressurize our glomeruli. Structural components are essential to podocyte function and it is possible that lack of oncotic or hydrostatic pressure, flow, or membrane stretch may impact purinergic response. This is particularly of note as P2X4 has been proposed to function as a mechanosensory protein in podocytes to modify cytoskeletal organization, and lack of mechanical perturbation may be the reason we do no observe P2X4 activity in healthy podocytes (Forst et al., 2016). Lastly, while it is likely that excessive Ca²⁺ signaling from ionotropic P2 receptors in diabetic podocytes exacerbates podocyte damage, whether this remodeling is causative and occurs in early stages of the disease in podocytes or is a response to early pathological changes is still up for debate. Repeating these experiments with conditional or cell-specific knockouts or in glucose-controlled diabetic animals in future experiments could help uncover this chicken or egg dilemma.

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Animals
- METHOD DETAILS
  - Glomeruli isolation
  - Confocal calcium imaging in the podocytes of freshly isolated glomeruli
  - Western blotting
  - mRNA isolation and PCR analysis
  - Immunofluorescence labeling
- QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.isci.2021.102528.

ACKNOWLEDGMENTS

This work was supported by Department of Veterans’ Affairs, Grant I01 BX004024 (to AS), National Institutes of Health Grants R35 HL135749 (to AS), R00 DK105160 to (DVI), and T32 HL134643 (CVC A.O. Smith Fellowship to CAK), R01 DK126720 (to OP), and NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255 (to AS).

AUTHOR CONTRIBUTIONS

OP, CAK, EI, DVI, and AS designed the study; OP, CAK, EI, VVL, DS, LVD, and DVI performed the investigations; DVI, OP, CAK, LVD, ON, and EI analyzed the data; OP, CAK, EI, and DVI made the figures; OP, CAK, EI, DVI, and AS drafted and revised the paper. All authors approved the final version of the manuscript.
DECLARATION OF INTERESTS

The authors declare no competing interests.

REFERENCES

Arkhipov, S.N., Potter, D.L., Geurts, A.M., and Pavlov, T.S. (2019). Knockout of P2X7 purinergic receptor attenuates cyst growth in a rat model of ARPKD. Am. J. Physiol. Ren. Physiol. 317, F1649–F1655.

Burford, J.L., Villanueva, K., Lam, L., Riquier-Boron, A., Hackler, L., Pippin, J., Shankland, S.J., and Peti-Peterdi, J. (2014). Intravitral imaging of podocyte calcium in glomerular injury and disease. J. Clin. Invest. 124, 2050–2058.

Burnstock, G., and Novak, I. (2013). Purinergic signalling and diabetes. Purinergic Signal. 9, 307–324.

Chang, M.Y., Lu, J.K., Tian, Y.C., Chen, Y.C., Hung, C.C., Huang, Y.H., Chen, Y.H., Wu, M.S., Yang, C.W., and Cheng, Y.C. (2011). Inhibition of the P2X7 receptor reduces cystogenesis in PKD. J. Am. Soc. Nephrol. 22, 1696–1706.

Chen, K., Zhang, J., Zhang, J., Yang, J., Li, K., and He, Y. (2013). ATP-P2X4 signaling mediates NLRP3 inflammasome activation: a novel pathway of diabetic nephropathy. Int. J. Biochem. Cell Biol. 45, 932–943.

Chung, J.J., Goldstein, L., Chen, Y.J., Lee, J., Webster, J.D., Roose-Girma, M., Paudyal, S.C., Modrusan, Z., Dey, A., and Shaw, A.S. (2020). Single-cell transcriptional profiling of the kidney glomerulus identifies Key cell types and reactions to injury. J. Am. Soc. Nephrol. 31, 2341–2354.

Craigie, E., Birch, R.E., Unwin, R.J., and Wildman, S.S. (2013). The relationship between P2X4 and P2X7- a physiologically important interaction? Front. Physiol. 4, 218.

Fischer, K.G., Saueressig, U., Jacobshagen, C., Wichelmann, A., and Pavent, H. (2001). Extracellular nucleotides regulate cellular functions of podocytes in culture. Am. J. Physiol. Ren. Physiol. 281, F1075–F1081.

Fleckenstein, A., Frey, M., and Fleckenstein-Grun, G. (1983). Consequences of uncontrolled calcium entry and its prevention with calcium antagonists. Eur. Heart J. 4, 43–50.

Forst, A.L., Olteanu, V.S., Mollet, G., Wlodkowski, T., Schaefer, F., Dietrich, A., Reiser, J., Gudermann, T., Mederos y Schnitzler, M., and Storch, U. (2016). Podocyte purinergic P2X4 channels are mecanotransducers that mediate cytoskeletal disorganization. J. Am. Soc. Nephrol. 27, 884–882.

Fu, J., Akat, K.M., Sun, Z., Zhang, W., Schlondorff, D., Liu, Z., Tschili, L., Lee, K., and He, J.C. (2019). Single-cell RNA profiling of glomerular cells shows dynamic changes in experimental diabetic kidney disease. J. Am. Soc. Nephrol. 30, 533–545.

Goncalves, R.G., Gabrič, L., Rosario, A., Jr., Takiya, C.M., Ferreira, M.L., Chiariini, L.B., Persechini, P.M., Coutinho-Silva, R., and Leite, M., Jr. (2006). The role of purinergic P2X7 receptors in the inflammation and fibrosis of unilateral ureteral obstruction in mice. Kidney Int. 70, 1599–1606.

Goto, Y., Kakizaki, M., and Masaki, N. (1976). Production of spontaneous diabetic rats by repetition of selective breeding. Tohoku J. Exp. Med. 119, 85–90.

Guo, C., Masin, M., Qureshi, O.S., and Murrell-Lagagnino, R.D. (2007). Evidence for functional P2X4/P2X7 heteromeric receptors. Mol. Pharmacol. 72, 1447–1456.

Han, S.J., Lovasz, M., Kim, M., D’Agati, V., Hasko, G., and Lee, H.T. (2020). P2X4 receptor exacerbates ischaemic AKI and induces renal proximal tubular NLRP3 inflammasome signaling. FASEB J. 34, 5456–5482.

Hillman, K.A., Burnstock, G., and Unwin, R.J. (2005). The P2X7 ATP receptor in the kidney: a matter of life or death? Nephron Exp. Nephrol. 107, e24–30.

Ilatovskaya, D.V., Blass, G., Palygin, O., Levchenko, V., Pavlov, T.S., Gryzovskii, M.N., Winsor, K., Shuyssky, L.S., Geurts, A.M., Cowley, A.W., Jr., et al. (2018). A NOX4/TRPC6 pathway in podocyte calcium regulation and renal damage in diabetic kidney disease. J. Am. Soc. Nephrol. 29, 1917–1927.

Ilatovskaya, D.V., Levchenko, V., Lowing, A., Shuyssky, L.S., Palygin, O., and Staruschenko, A. (2015). Podocyte injury in diabetic nephropathy: implications of angiotensin II-dependent activation of TRPC channels. Sci. Rep. 5, 17637.

Ilatovskaya, D.V., Palygin, O., Levchenko, V., and Staruschenko, A. (2013). Pharmacological characterization of the P2 receptors profile in the podocytes of the freshly isolated rat glomeruli. Am. J. Physiol. Cell Physiol. 305, C1050–C1059.

Ji, X., Naito, Y., Weng, H., Endo, K., Ma, X., and Iwai, N. (2012). P2X7 deficiency attenuates hypertension and renal injury in deoxycorticosterone acetate-salt hypertension. Am. J. Physiol. Ren. Physiol. 303, F1207–F1215.

Komer, A., Jaremko, G., Eklof, A.C., and Aperia, A. (1997). Rapid development of glomerulosclerosis in diabetic Dahl salt-sensitive rats. Diabetologia 40, 367–373.

Menzies, R.I., Howarth, A.R., Unwin, R.J., Tam, F.W., Mullins, J.J., and Bailey, M.A. (2015). Inhibition of the purinergic P2X7 receptor improves renal perfusion in angiotensin-II-infused rats. Kidney Int. 88, 1079–1087.

Menzies, R.I., Tam, F.W., Unwin, R.J., and Bailey, M.A. (2017a). Purinergic signaling in kidney disease. Kidney Int. 91, 315–323.

Miller, B.S., Blumenthal, S.R., Shalygin, A., Wright, K.D., Staruschenko, A., Imig, J.D., and Sorokin, A. (2018). Inactivation of p66Shc decreases afferent arteriolar KATP channel activity and decreases renal damage in diabetic Dahl SS rats. Diabetes 67, 2206–2212.

Mironova, E., Suliman, F., and Stockand, J.D. (2019). Renal Na(+) excretion consequent to pharmacogenetic activation of Glu(o)-DREADD in principal cells. Am. J. Physiol. Ren. Physiol. 316, F758–F767.

Mitrofanova, A., Sosa, M.A., and Fornoni, A. (2019). Lipid mediators of insulin signaling in diabetic kidney disease. Am. J. Physiol. Ren. Physiol. 317, F1241–F1252.

Nickle, A. (2008). Homotrimmeric complexes are the dominant assembly state of native P2X7 subunits. Biochem. Biophys. Res. Commun. 377, 803–808.

Nicotera, P., and Orrenius, S. (1998). The role of calcium in apoptosis. Cell Calcium 23, 173–180.

Nobrega, M.A., Fleming, S., Roman, R.J., Shiozawa, M., Schlick, N., Lazar, J., and Jacob, H.J. (2004). Initial characterization of a rat model of diabetic nephropathy. Diabetes 53, 735–742.

Palygin, O., Evans, L.C., Cowley, A.W., Jr., and Staruschenko, A. (2017). Acute in vivo analysis of ATP release in rat kidneys in response to changes of renal perfusion pressure. J. Am. Heart Assoc. 6, e006658.

Palygin, O., Ilatovskaya, D.V., Levchenko, V., Klemens, C.A., Dissanayake, L., Williams, A.M., Pavlov, T.S., and Staruschenko, A. (2018). Characterization of purinergic receptor expression in ARPKD cystic epithelia. Purinergic Signal. 14, 485–497.

Palygin, O., Levchenko, V., Ilatovskaya, D.V., Klemens, C.A., Dissanayake, L., Williams, A.M., Pavlov, T.S., and Staruschenko, A. (2017). Real-time electrochemical detection of ATP and H2O2 release in freshly isolated kidneys. Am. J. Physiol. Ren. Physiol. 305, F134–F141.

Palygin, O., Spires, D., Levchenko, V., Bohosyv, R., Fedoruk, M., Klemens, C.A., Sylkes, O., Bukowy, J.D., Cowley, A.W., Jr., Lazar, J., et al. (2019). Progression of diabetic kidney disease in...
T2DN rats. Am. J. Physiol. Ren. Physiol. 317, F1450–F1461.

Pereira, J.M.S., Barreira, A.L., Gomes, C.R., Ornelas, F.M., Ornelas, D.S., Miranda, L.C., Cardoso, L.R., Coutinho-Silva, R., Schinaider, A., Morales, M.M., et al. (2020). Brilliant blue G, a P2X7 receptor antagonist, attenuates early phase of renal inflammation, interstitial fibrosis and is associated with renal cell proliferation in ureteral obstruction in rats. BMC Nephrol. 21, 208.

Perez-Flores, G., Levesque, S.A., Pacheco, J., Vaca, L., Lacroix, S., Perez-Cornejo, P., and Arreola, J. (2015). The P2X7/P2X4 interaction shapes the purinergic response in murine macrophages. Biochem. Biophys. Res. Commun. 467, 484–490.

Potthoff, S.A., Stegbauer, J., Becker, J., Wagenhaeuser, P.J., Duvnjak, B., Rump, L.C., and Vonend, O. (2013). P2Y2 receptor deficiency aggravates chronic kidney disease progression. Front. Physiol. 4, 234.

Rizzuto, R., Pinton, P., Ferrari, D., Chami, M., Magalhaes, P.J., Di Virgilio, F., and Pozzan, T. (2003). Calcium and apoptosis: facts and hypotheses. Oncogene 22, 8619–8627.

Roshanravan, H., and Dryer, S.E. (2014). ATP acting through P2Y receptors causes activation of podocyte TRPC6 channels: role of podocin and reactive oxygen species. Am. J. Physiol. Ren. Physiol. 306, F1088–F1097.

Schneider, M., Prudic, K., Pippel, A., Klapperstuck, M., Braam, U., Muller, C.E., Schmalzing, G., and Markwardt, F. (2017). Interaction of purinergic P2X4 and P2X7 receptor subunits. Front. Pharmacol. 8, 860.

Schwiebert, E.M., and Zembehry, A. (2003). Extracellular ATP as a signaling molecule for epithelial cells. Biochim. Biophys. Acta 1675, 7–32.

Slaughter, T.N., Paige, A., Spires, D., Kojima, N., Kyle, P.B., Garrett, M.R., Roman, R.J., and Williams, J.M. (2013). Characterization of the development of renal injury in Type-1 diabetic Dahl salt-sensitive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 305, R727–R734.

Solini, A., Menini, S., Rossi, C., Ricci, C., Santini, E., Binesetti Fantauzzi, C., Iacobini, C., and Pugliese, G. (2013). The purinergic 2X7 receptor participates in renal inflammation and injury induced by high-fat diet: possible role of NLRP3 inflammasome activation. J. Pathol. 231, 342–353.

Stockand, J.D., Mizanova, E., Bugay, V., Rieg, T., Insel, P.A., Vallon, V., Peti-Peterdi, J., and Pochynyuk, O. (2010). Purinergic inhibition of ENaC produces aldosterone escape. J. Am. Soc. Nephrol. 21, 1903–1911.

Taylor, S.R., Turner, C.M., Elliott, J.I., McDaid, J., Hewitt, R., Smith, J., Pickering, M.C., Whitehouse, D.L., Cook, H.T., Burnstock, G., et al. (2009a). P2X7 deficiency attenuates renal injury in experimental glomerulonephritis. J. Am. Soc. Nephrol. 20, 1275–1281.

Taylor, S.R., Turner, C.M., Elliott, J.I., McDaid, J., Hewitt, R., Smith, J., Pickering, M.C., Whitehouse, D.L., Cook, H.T., Burnstock, G., et al. (2009b). P2X7 deficiency attenuates renal injury in experimental glomerulonephritis. J. Am. Soc. Nephrol. 20, 1275–1281.

Umanath, K., and Lewis, J.B. (2018). Update on diabetic nephropathy: core curriculum 2018. Am. J. Kidney Dis. 71, 884–895.

Vallon, V., and Komers, R. (2011). Pathophysiology of the diabetic kidney. Compr. Physiol. 1, 1175–1232.

Vallon, V., Unwin, R., Inscho, E.W., Leipziger, J., and Kishore, B.K. (2020). Extracellular nucleotides and P2 receptors in renal function. Physiol. Rev. 100, 211–269.

Vonend, O., Turner, C.M., Chan, C.M., Loesch, A., Dell’Anna, G.C., Srai, K.S., Burnstock, G., and Unwin, R.J. (2004a). Glomerular expression of the ATP-sensitive P2X receptor in diabetic and hypertensive rat models. Kidney Int. 66, 157–166.

Vonend, O., Turner, C.M., Chan, C.M., Loesch, A., Dell’Anna, G.C., Srai, K.S., Burnstock, G., and Unwin, R.J. (2004b). Glomerular expression of the ATP-sensitive P2X receptor in diabetic and hypertensive rat models. Kidney Int. 66, 157–166.

Wilson, P.C., Wu, H., Krita, Y., Uchimura, K., Ledru, N., Renkke, H.G., Welling, P.A., Waikar, S.S., and Humphreys, B.D. (2019). The single-cell transcriptomic landscape of early human diabetic nephropathy. Proc. Natl. Acad. Sci. U S A 116, 19619–19625.

Xia, J.F., Liang, Q.L., Hu, P., Wang, Y.M., Li, P., and Luo, G.A. (2009). Correlations of six related purine metabolites and diabetic nephropathy in Chinese type 2 diabetic patients. Clin. Biochem. 42, 215–220.
### STAR★METHODS

#### KEY RESOURCES TABLE

| REAGENT OR RESOURCE | SOURCE | IDENTIFIER |
|----------------------|--------|------------|
| **Antibodies**       |        |            |
| P2Y1                 | Alomone| Cat# APR-021, RRID:AB_10919250 |
| P2Y2                 | Alomone| Cat# APR-010, RRID:AB_2040078  |
| P2Y12                | Alomone| Cat# APR-012, RRID:AB_2040074  |
| P2X4                 | Alomone| Cat# APR-002, RRID:AB_2040058  |
| P2X7                 | Alomone| Cat# APR-004, RRID:AB_2040068  |
| P2X7 ext             | Alomone| Cat# APR-008, RRID:AB_2040065  |
| Gapdh                | SantaCruz| Cat# sc-47724, RRID:AB_627678 |
| Nephrin              | SantaCruz| Cat# sc-377246 |
| Donkey anti-mouse Alexa-488 | Invitrogen| Cat# A21202, RRID:AB_141607 |
| Donkey anti-rabbit Alexa-594 | Invitrogen| Cat# A21207, RRID:AB_141637 |
| **Chemicals, peptides, and recombinant proteins** | | |
| RPMI1640             | Invitrogen| Cat# 11835-030 |
| BSA                  | Sigma  | Cat# A3059  |
| Fluoromount-G        | ThermoFisher| Cat# 00-4958-02 |
| TRizol               | ThermoFisher| Cat# 15596026 |
| ATP                  | Sigma  | Cat# A6559  |
| Insulin pellets      | LinShin Canada Inc.| Cat# LHR-10BV |
| Streptozotocin (STZ) | Sigma  | Cat# 50130  |
| MRS2500              | Tocris | Cat# 2159   |
| 5-BDBD               | Tocris | Cat# 3579   |
| A 438079             | Tocris | Cat# 2972   |
| DMSO                 | Sigma  | Cat# 276855 |
| **Critical commercial assays/kits** | | |
| Creatinine Assay     | Cayman Chemical| Cat# 500701 |
| Albumin Assay        | Active Motif| Cat# 15002 |
| RevertAid First Strand cDNA Synthesis Kit | ThermoSci| Cat# K1621 |
| **qPCR primers**     |        | N/A        |
| P2X4                 | This paper| N/A        |
| Forward GACGTGGCGGACTATGATGAT | Reverse TCTTCCAGTGCAACTCCAC |
| P2X7                 | This paper| N/A        |
| Forward CAAAGGTCAAGGTCCCGAGAC | Reverse GCCCTGCGGTTCTTGTTAG |
| P2Y1                 | This paper| N/A        |
| Forward GGCCGACTTTTTGTATGTGCTC | Reverse TCCCGAAGATCCAGTGTC |
| P2Y2                 | This paper| N/A        |
| Forward TCGTGCCCTCTCAGTCTCC | Reverse CACCCTGGCGTAGTAATAAACC |
| Gapdh                | This paper| N/A        |
| Forward GGCAAAATTCCACGGCACAGT | Reverse AGATGGTGGGGCTTCC C |

(Continued on next page)
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Alexander Staruschenko (staruschenko@mcw.edu).

Materials availability
This study did not generate new unique reagents.

Data and code availability
The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Animals
The animal use and welfare procedures adhered to the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals following protocols reviewed and approved by the Medical College of Wisconsin (MCW) Institutional Animal Care and Use Committee. To assess renal purinergic P2 signaling in T2D, male Wistar (nondiabetic), Goto-Kakizaki (GK; T2D), and T2DN rats at different ages (12 and >48 weeks old) were used. Wistar male rats were purchased from Charles River Laboratories. GK and T2DN rats have been inbred for multiple generations at MCW. Animals were fed a regular diet (#5001, LabDiet, Purina) with water and food provided ad libitum. Streptozotocin (STZ)-injected Dahl salt-sensitive (SS) rats (SS/JrHsdMcwi) were used to characterize P2-dependent calcium dynamics in podocytes in the conditions of T1D. Briefly, 65 mg/kg of streptozotocin was dissolved in citrate buffer and immediately administered via intraperitoneal injection (Ilatovskaya et al., 2015; Miller et al., 2018; Slaughter et al., 2013; Spires...
et al., 2018). SS rats were also inbred for multiple generations at MCW and maintained on a 0.4% NaCl AIN-76 diet (#D113755, Dyets) in a standard 12/12 dark/light cycle. 8- to 9-week old SS rats were injected with STZ to induce T1D. Four days after injection, blood glucose levels were tested to verify successful beta-cell ablation as determined by blood glucose levels ≥ 300mg/dL, then implanted with a long-acting subcutaneous insulin pellet between scapulae (LinShin, Canada) to maintain moderate hyperglycemia as described (Ilatovskaya et al., 2015). Blood glucose levels, as determined by tail prick blood samples measured by a glucometer, were checked periodically (2, 6, 12, and 14 weeks). At the end of the experiment, urine samples collected for 24 hours in metabolic cages were used to determine volume, microalbumin and creatinine levels. Urinary microalbumin concentrations were determined by an albumin blue fluorescent assay kit (Active Motif) and read by a fluorescent plate reader (FL600, Bio-Tek). Urinary creatinine levels were determined by assay kit from Cayman Chemical. Albumin to Creatinine ratios (ACR) were determined by dividing microalbumin concentrations (mg/ml) by creatinine concentrations (mg/ml).

METHOD DETAILS
Glomeruli isolation
Freshly isolated kidney cortex was minced and sequentially pushed through a steel 150 μm mesh sieve and then pipetted through a 106 μm mesh sieve (#04-881-SZ and #04-881-SX, Fisher Sci) using the culture medium solution RPMI1640 (Invitrogen) with 5% BSA (RPMI-BSA solution). This tissue homogenate was then pipetted onto a 73.7 μm mesh sieve (#54145; Sigma), leaving the glomeruli on the top surface. The glomeruli were rinsed using the RPMI-BSA solution into a 15 ml conical tube and pelleted for 10-15 min on ice. After sedimentation, the excess RPMI-BSA solution was removed, and the isolated decapsulated glomeruli were used for confocal microscopy experiments as described below.

Confocal calcium imaging in the podocytes of freshly isolated glomeruli
Glomeruli were imaged using confocal microscopy immediately after isolation. Glomerular fractions were loaded with Fura Red and Fluo-4 AM (2.5 μM of each, #F3021 and #F23917, correspondingly, Invitrogen) dyes for ~ 40 min at room temperature, then transferred to poly-L-lysine coated coverslips, allowed to attach to the glass surface for 5-10 min, and, then washed twice with a solution containing (in mM): 145 NaCl, 4.5 KCl, 2 CaCl₂, 2 MgCl₂, 10 HEPES, pH 7.35. Calcium imaging was performed on a Leica TCS SP5 63x/1.4 oil objective (x,y,t; 2.46 sec per frame) controlled by Leica Application Suite X software. For initial experiments measuring basal [Ca²⁺], and ATP response in 12 week old T2DN rats, fluorescence measurements were obtained on the confocal laser scanning microscope system Nikon A1-R (oil immersed Plan Apo 60x/NA 1.4 Oil objective) with the argon laser synchronous excitation at 488 nm and selective transmission of light through the emission filters 520/25 and 680/25 for Fluo-4 and Fura Red, respectively. Ratiometric fluorescence images of Fluo-4 (excitation at 488 nm and emission at 520 ± 20 nm) and Fura Red (excitation at 488 nm and emission at >600 nm) were obtained with the same instrument settings for all experiments in times series (x,y,t, 4 seconds per frame) (Ilatovskaya et al., 2018). In some experiments, Fura Red was replaced with Fura 2-TH (ex. 488 em. >600 nm; #51419, Setareh Biotech, OR). Fluorescence images were collected with 0.25 Hz frequency and processed with open-source software Fiji (ImageJ 1.47v, National Institute of Health, USA). [Ca²⁺]_i concentration in podocytes preloaded with Fluo-4 and Fura Red was measured by application of 10 μM ionomycin followed by addition of 1 mM MnCl₂ to the bath solution. The bath solution contained (in mM) 145 NaCl, 4.5 KCl, 2 MgCl₂, 2 CaCl₂ and 10 HEPES (pH 7.35) (Palygin et al., 2018). The ratiometric fluorescence intensity values (Fluo4/FuraRed) were calculated by selecting podocytes as regions of interest in Fiji and baseline correction was performed in OriginPro 9.0 (MicroCal, Northhampton, MA). Individual Ca²⁺ transients evoked by the extracellular application of ATP in the presence or absence of corresponding P2 receptors inhibitors were baselined and summarized for all podocytes (at least 6 glomeruli per group from ≥ 4 animals). There was no significant difference between water or DMSO vehicle treated control glomeruli. We evaluated the changes in Ca²⁺ transient maximum amplitude or [Ca²⁺]_i (area under the curve) within the time interval from the start of the application until 400 s. To determine the relative contribution of different components of purinergic signaling (metabotropic and ionotropic) to the ATP response, we calculated the % of [Ca²⁺]_i response from control (bulk ATP response, no inhibitors) from [Ca²⁺]_i, flux values in the presence of a specific antagonist or combination of inhibitors.

Western blotting
For preparation of kidney lysates, cortical sections were collected at the same time as glomerular isolation, snap frozen in liquid nitrogen, then weighed and dissolved in Laemmli with protease and phosphatase
inhibitors (Roche) at 20 mg/ml with pulse sonication for 15-20 sec. Samples were subjected to SDS-PAGE, transferred onto nitrocellulose membrane (Millipore) for antibody hybridization, and subsequently visualized by enhanced chemiluminescence (ECL; Amersham Biosciences). See Key Resources table for antibodies used for Western blot analysis.

**mRNA isolation and PCR analysis**

Total RNA from flash frozen cortical kidney sections was isolated using TRizol Reagent (ThermoFisher) according to manufacturer’s protocol. Total RNA quantity was determined by Nanodrop 2000 (ThermoFisher). RNA quality was verified using Agilent 2100 Bioanalyzer, and only samples with RNA integrity numbers (RIN) greater than 8 were used. cDNA from 2µg of RNA was generated using the RevertAid First Strand cDNA Synthesis Kit (ThermoFisher) with random hexamer primers. Real-time PCR reactions were carried out on an ABI Prism 7900HT (ABI, Applied Biosystems, Foster City, CA) using Bullseye EvaGreen qPCR Master Mix (MedSci, Valley Park, MO) according to manufacturer’s directions with samples run in triplicate. Final Ct values were determined using SDS software, version 2.3. Exon spanning primers were designed from the rat sequences of P2rx4, P2rx7, P2ry1, P2ry2 and Gapdh (see Key Resources Table). Quantification of P2rx4, P2rx7, P2ry1 and P2ry2 mRNA was determined by normalizing to Gapdh.

**Immunofluorescence labeling**

Freshly-isolated glomeruli were allowed to adhere to twice coated poly-l-lysine coverslips before washing with PBS and fixing with 4% paraformaldehyde in PBS for 20 minutes. Following 3x washes with PBS, glomeruli were blocked and permeabilized with 2% BSA + 0.25% Triton-X in PBS. Primary antibodies (1:100; Nephrin sc-377246, P2X4 APR-002) were diluted in 2% BSA in PBS overnight at 4°C. The next day, glomeruli were washed 3x with PBS then incubated with Alexa-labeled secondary antibodies (1:500) for 1 hr at room temperature in 2% BSA in PBS. Following 3x washes with PBS, nuclei were labeled with 0.5 µg/mL Hoescht for 5 min, washed 5x with PBS and then mounted onto slides with Fluoromount-G. Images with 2 µm z-steps were captured on a Nikon A1R confocal inverted microscope using a Plan Apo ×40 DIC M N2 objective with 0.95 numerical aperture controlled by Nikon Elements AR software (Nikon, Tokyo, Japan). Post-image processing was performed with Fiji image software.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

Data are presented as means ± SEM. In the box plot graphs, the box represents ± SE, and a line inside the box marks the median. The whiskers are ± SD. Data were tested for normality (Shapiro-Wilk) and equal variance (Levene’s homogeneity test). Statistical analysis consisted of one-way ANOVA or student t-test as indicated (SigmaPlot 12.5 or OriginPro 9.0), with a p-value of <0.05 considered significant. Dunnett’s or Tukey multiple-comparisons adjustment was applied to all pairwise p-values as indicated in the figure legends.